PremiumMarket NewsCorcept Therapeutics Stock (CORT) Rockets Up 100% After Groundbreaking Cancer Trial Success Corcept Therapeutics price target raised to $142 from $130 at Canaccord Buy Recommendation for Corcept Therapeutics Driven by Promising Phase 3 ROSELLA Study Results and Market Expansion Potential PremiumRatingsPromising Phase 3 Results and Market Potential Drive Buy Rating for Corcept Therapeutics Corcept Therapeutics price target raised to $150 from $115 at H.C. Wainwright Corcept Therapeutics announces ROSELLA trial meets primary endpoint PremiumCompany AnnouncementsCorcept Therapeutics’ Earnings Call Highlights Growth and Challenges Corcept Therapeutics price target raised to $78 from $67 at Piper Sandler Corcept Therapeutics: Strong Financial Outlook and Promising Clinical Developments Support Buy Rating 
